Medicine in focus
Revisiting the seed and soil in cancer metastasis

https://doi.org/10.1016/j.biocel.2009.01.015Get rights and content

Abstract

Metastasis remains the overwhelming cause of death for cancer patients. During metastasis, cancer cells will leave the primary tumor, intravasate into the bloodstream, arrest at a distant organ, and eventually develop into gross lesions at the secondary sites. This intricate process is influenced by innumerable factors and complex cellular interactions described in 1889 by Stephen Paget as the seed and soil hypothesis. In this review, we revisit this seed and soil hypothesis with an emerging understanding of the cancer cell (i.e. seed) and its microenvironment (i.e. soil). We will provide background to suggest that a critical outcome of the seed–soil interaction is resistance of the stresses that would otherwise impede metastasis.

Introduction

The cause of death for the vast majority of cancer patients is the development of metastatic lesions at sites distant from that of the primary tumor. Metastasis describes both the process of cancer spread (i.e. the verb, describing the events that characterize the spread of cancer) and the resultant secondary cancer (i.e. noun, describing the actual metastatic lesion). Since most cancer patients present with localized disease that is effectively managed with multimodality therapies including surgery, radiation, and chemotherapy, the development of metastasis at distant secondary organs must involve the dissemination of metastatic cells before patients present with a primary tumor. Based on the work of several groups, it is believed that the process of metastasis (i.e. the verb) involves tumor cells leaving the primary tumor through a well-regulated lysis of surrounding stroma. These cells must pass through the tumor basement membrane and then through or between endothelial cells in order to enter the circulation. While in the circulation, a tumor cells must resist the process of anoikis (programmed cell death associated with loss of cellular contact), evade immune recognition, cope with the sheer physical stress of the circulatory system, and eventually arrest at a distant organ. At the distant site, the cell must exit the circulation, survive the stresses of a new and likely hostile microenvironment, proliferate, induce angiogenesis and/or co-opt existing blood vessels, and then successfully grow into a measurable metastatic lesion (Steeg and Theodorescu, 2008).

The timing, pattern and sites for the spread of cancer are in part defined by the specific cancer type. The route of spread of cancer may include blood stream (hematogenous), lymphatic vessels, or third space extension (i.e. ascitic fluid dissemination as seen in ovarian cancer). The site of distant metastasis may include regional lymph nodes, or visceral organs such as lungs, liver, brain, and bone. While Weiss et al. (1988) have shown that the primary site of metastases tends to occur at the first capillary bed encountered, it is increasingly believed that the specific site of distant metastasis is not simply to be due to anatomic location of the primary tumor or proximity to secondary sites but rather, involves interactions between tumor cells and the local microenvironment at the secondary site.

For many reasons, metastatic lesions are often not amenable to the surgical cures achieved in the management of the primary tumor. First, the development of metastases at distant secondary organs is often so widespread that surgery is not possible. In addition, the organs in which metastases develop may not be able to accommodate the necessary wide surgical margins needed for cure (i.e. brain). For many cancers, metastatic lesions themselves demonstrate increased resistance to conventional treatment modalities (i.e. chemotherapy). This resistance to therapy may be acquired as a result of past treatment of the patient or may be an innate feature of cells that have successfully negotiated the metastatic process. Based on the challenges that metastatic disease presents, new treatment options are needed in order to decrease morbidity and mortality.

Stephen Paget's seed and soil hypothesis suggested that the sites where metastases occur are defined not only by the tumor cell (“seed”) but also the microenvironment of the secondary metastatic site (“soil”). Recent data have shed new light on the acquisition of the “seeds” of metastasis, suggesting that some of the features of this tumor cell phenotype are conveyed early in the process of oncogenesis, whereas others are selected for during cancer progression (Scheel et al., 2007, Talmadge, 2007). Indeed, many of the features of the tumor cells (“seed”) now appear to be shared with primitive stem-like cells capable of not only tumor-initiation but also metastasis (Mehlen and Puisieux, 2006, Croker and Allan, 2008, Vermeulen et al., 2008). An attractive link between the tumor-initiating cell (cancer stem cell) hypothesis and metastasis is the programming and ability of these stem-like, self-renewing and multipotent cells to resist stress, perhaps facilitated by their abilities to engage and develop connections with specific microenvironments (“soil”). In this review we will consider new data that describe the tumor cell, its microenvironment, and connections between the two as a critical means to resist the stresses that cells encounter during metastatic progression.

Section snippets

Characteristics and emergence of the tumor cell (the “seed”)

The emergence of the metastatic phenotype within a primary tumor has been explained as a process that happens late in carcinogenesis. This hypothesis holds that tumor cells possessing the metastatic phenotype represent a very small fraction of cells within a heterogeneous primary tumor and that over time, a small proportion of tumor cells gain the attributes necessary for metastasis (Fidler and Kripke, 1977). In testing of this hypothesis, Varmus and colleagues were able to show untransformed

Acknowledgements

The authors would like to thank Drs. Joseph W. Briggs, Sung-Hyeok Hong, Lalage Wakefield, and Glenn Merlino for helpful comments and critical reading of the manuscript.

References (246)

  • P.S. Craighead et al.

    A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer

    Int J Radiat Oncol Biol Phys

    (2000)
  • K. De Jaeger et al.

    Heterogeneity of tumor oxygenation: relationship to tumor necrosis, tumor size, and metastasis

    Int J Radiat Oncol Biol Phys

    (1998)
  • A. Enns et al.

    Alphavbeta5-integrins mediate early steps of metastasis formation

    Eur J Cancer

    (2005)
  • E. Fernandez-Salas et al.

    p53 and tumor necrosis factor alpha regulate the expression of a mitochondrial chloride channel protein

    J Biol Chem

    (1999)
  • D. Fukumura et al.

    Tumor induction of VEGF promoter activity in stromal cells

    Cell

    (1998)
  • M.V. Gustafsson et al.

    Hypoxia requires notch signaling to maintain the undifferentiated cell state

    Dev Cell

    (2005)
  • R.O. Hynes

    Integrins: bidirectional, allosteric signaling machines

    Cell

    (2002)
  • R.L. Juliano et al.

    Adhesion molecules in cancer: the role of integrins

    Curr Opin Cell Biol

    (1993)
  • B. Keith et al.

    Hypoxia-inducible factors, stem cells, and cancer

    Cell

    (2007)
  • K. Khazaie et al.

    The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer

    Semin Cancer Biol

    (2006)
  • P.A. Aeed et al.

    The role of polymorphonuclear leukocytes (PMN) on the growth and metastatic potential of 13762NF mammary adenocarcinoma cells

    Int J Cancer

    (1988)
  • S. Ambs et al.

    Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression

    FASEB J

    (1997)
  • B.C. Barnhart et al.

    Metastasis and stem cell pathways

    Cancer Metastasis Rev

    (2007)
  • R.C. Bates et al.

    Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma

    J Clin Invest

    (2005)
  • G. Bellone et al.

    Regulation of NK cell functions by TGF-beta 1

    J Immunol

    (1995)
  • D. Belotti et al.

    Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion

    Mol Cancer Res

    (2008)
  • A. Bertotti et al.

    Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis

    Cancer Res

    (2005)
  • A. Bertotti et al.

    Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth

    J Cell Biol

    (2006)
  • N.A. Bhowmick et al.

    Stromal fibroblasts in cancer initiation and progression

    Nature

    (2004)
  • B. Bierie et al.

    Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer

    Nat Rev Cancer

    (2006)
  • C. Binder et al.

    Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues

    Anticancer Res

    (1997)
  • C. Birchmeier et al.

    Met, metastasis, motility and more

    Nat Rev Mol Cell Biol

    (2003)
  • M.V. Blagosklonny et al.

    The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy

    Leukemia

    (2001)
  • C. Boccaccio et al.

    Invasive growth: a MET-driven genetic programme for cancer and stem cells

    Nat Rev Cancer

    (2006)
  • L. Borsig

    The role of platelet activation in tumor metastasis

    Expert Rev Anticancer Ther

    (2008)
  • G. Brideau et al.

    Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice

    Cancer Res

    (2007)
  • C. Brigati et al.

    Tumors and inflammatory infiltrates: friends or foes?

    Clin Exp Metastasis

    (2002)
  • D.M. Brizel et al.

    Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma

    Cancer Res

    (1996)
  • L.F. Brown et al.

    Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast

    Clin Cancer Res

    (1999)
  • N.S. Brown et al.

    Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer

    Breast Cancer Res

    (2001)
  • A.R. Cardones et al.

    CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin

    Cancer Res

    (2003)
  • P.T. Caswell et al.

    Integrin trafficking and the control of cell migration

    Traffic

    (2006)
  • J.D. Chandler et al.

    Expression and localization of GLUT1 and GLUT12 in prostate carcinoma

    Cancer

    (2003)
  • J.J. Chen et al.

    Tumor-associated macrophages: the double-edged sword in cancer progression

    J Clin Oncol

    (2005)
  • R.W. Cho et al.

    Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors

    Stem Cells

    (2008)
  • H.R. Christofk et al.

    The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth

    Nature

    (2008)
  • A. Ciampolillo et al.

    The IGF-I axis in thyroid carcinoma

    Curr Pharm Des

    (2007)
  • T. Cook et al.

    Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53

    Cancer Res

    (2004)
  • C. Cordon-Cardo et al.

    Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites

    Proc Natl Acad Sci U S A

    (1989)
  • L.M. Coussens et al.

    Inflammation and cancer

    Nature

    (2002)
  • Cited by (0)

    View full text